MS Clinical Trials in Maryland

37 active trials · 19 recruiting

37 active multiple sclerosis clinical trials have at least one study site in Maryland, 19 of them currently recruiting participants. Trials are listed from ClinicalTrials.gov and cover disease-modifying therapies, symptom treatments, rehabilitation and imaging studies.

Eligibility, contact details and the exact site address are on each trial's ClinicalTrials.gov record, linked from every trial page. MS Buddy also lists 5 MS treatment centers in Maryland; many trial sites are run from those centers, and your neurologist is the best first person to ask about joining a study.

Active MS trials with sites in Maryland

RecruitingPhase 3

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

Sponsor: TG Therapeutics, Inc.

Ublituximab · Placebo

25 states800 participantsDetails ›

Recruiting

Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

1 state2400 participantsDetails ›

RecruitingPhase 1

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Cilostazol · Leucovorin

1 state250 participantsDetails ›

RecruitingPhase 2

Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Methylprednisolone · Prednisone

1 state30 participantsDetails ›

Recruiting

Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

1 state3750 participantsDetails ›

RecruitingPhase 3

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Sponsor: Novartis Pharmaceuticals

Remibrutinib oral treatment · Ocrelizumab

18 states360 participantsDetails ›

RecruitingPhase 2

A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

Sponsor: Hoffmann-La Roche

Ocrelizumab Test Formulation · Ocrelizumab Reference Formulation

8 states182 participantsDetails ›

RecruitingPhase 1

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Sponsor: National Cancer Institute (NCI)

Biospecimen Collection · Nivolumab

19 states300 participantsDetails ›

RecruitingPhase 3

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Sponsor: Novartis Pharmaceuticals

Remibrutinib (blinded) · Placebo

10 states1275 participantsDetails ›

RecruitingPhase 3

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Sponsor: Sanofi

Frexalimab · Teriflunomide

35 states1600 participantsDetails ›

RecruitingPhase 1

Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

89 Zr-Df-crefmirlimab

1 state15 participantsDetails ›

Recruiting

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Sponsor: TG Therapeutics, Inc.

No Intervention

29 states500 participantsDetails ›

RecruitingPhase 3

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

Sponsor: Sanofi

Frexalimab · Placebo

38 states900 participantsDetails ›

RecruitingNA

Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis

Sponsor: Accelerated Cure Project for Multiple Sclerosis

Online Program for Fatigue

6 states2000 participantsDetails ›

Recruiting

A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring

Sponsor: Bristol-Myers Squibb

1 state1182 participantsDetails ›

RecruitingPhase 2

A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

Sponsor: Tiziana Life Sciences LTD

Foralumab · Placebo

5 states54 participantsDetails ›

Recruiting

Pathological Basis of MRI Signal Changes in Multiple Sclerosis

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

1 state250 participantsDetails ›

RecruitingPhase 2

Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

Sponsor: Johns Hopkins University

Solriamfetol · Placebo

1 state46 participantsDetails ›

Recruiting

Genes and Environment in Multiple Sclerosis

Sponsor: Columbia University

4 states5000 participantsDetails ›

By invitation only

Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab

Sponsor: Johns Hopkins University

Ofatumumab

1 state75 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab

16 states769 participantsDetails ›

Closed to new patientsPhase 3

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Sponsor: Novartis Pharmaceuticals

Remibrutinib · Teriflunomide

23 states1011 participantsDetails ›

Closed to new patientsPhase 4

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Sponsor: Novartis Pharmaceuticals

Ofatumumab · Disease modifying treatment (DMT)

19 states136 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Fenebrutinib · Ocrelizumab

24 states985 participantsDetails ›

Closed to new patientsPhase 2

Ketamine for Multiple Sclerosis Fatigue

Sponsor: Johns Hopkins University

Ketamine · Midazolam

1 state110 participantsDetails ›

Closed to new patientsPhase 3

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

Sponsor: Novartis Pharmaceuticals

Ofatumumab approved dose · Ofatumumab new dose

24 states196 participantsDetails ›

Closed to new patientsPhase 3

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Sponsor: Novartis Pharmaceuticals

Remibrutinib · Teriflunomide

27 states1001 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Sponsor: Hoffmann-La Roche

Fenebrutinib · Teriflunomide

23 states746 participantsDetails ›

Closed to new patientsNA

The Use of Technology to Improve MS Clinical Trials and Patient Care

Sponsor: Johns Hopkins University

Communication with the clinic

1 state150 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab Placebo

11 states188 participantsDetails ›

Closed to new patientsNA

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Sponsor: Johns Hopkins University

Natalizumab/natalizumab-sztn, Alemtuz… · Glatiramer acetate, Interferons (intr…

28 states900 participantsDetails ›

Closed to new patients

Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis

Sponsor: The Cleveland Clinic

MRI

9 states420 participantsDetails ›

Closed to new patients

Biobank For MS And Other Demyelinating Diseases

Sponsor: Accelerated Cure Project for Multiple Sclerosis

9 states3226 participantsDetails ›

Closed to new patientsPhase 1

ABA-101 in Participants With Progressive Multiple Sclerosis

Sponsor: Abata Therapeutics

ABA-101

3 states12 participantsDetails ›

Closed to new patients

A Post-Authorization, Long-term Study of Ozanimod Real-world Safety

Sponsor: Bristol-Myers Squibb

1 state9000 participantsDetails ›

Closed to new patientsPhase 2

Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

tolebrutinib 60mg · tolebrutinib 120mg

1 state12 participantsDetails ›

Closed to new patientsPhase 2

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

Sponsor: Immunic AG

IMU-838 · Placebo matching IMU-838

6 states450 participantsDetails ›

The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.

Active MS trials with sites in Maryland

MS trials in other states